APSCVIR 2021 Taipei - The Art of Breaking Boundaries

Programme

Programme Day2
Saturday 2021/2/27

	A	B	C	D
8:30	APSCVIR meets SIR
8:45
9:00
9:15
9:30
9:45
10:00
10:00-10:30	Break
10:30	GI Vessel Occlusion	HCC	Y-90 symposium SIR 10:30-11:30	APSCVIR meets SPIR
10:45
11:00
11:15
11:30			Y-90 symposium TSIR 11:30-12:15
11:45
12:15
12:15-13:30	Cook Lunch Symposium 2A	Guerbet Lunch Symposium 2B	BD Lunch Symposium 2C
13:30	Liver Transplant	APSCVIR meet APCIO	Vascular-Aorta Endoleak & Leriche	Oral presentation 1
13:30
15:00
15:00
15:00
15:00
15:00
15:00-15:30	Break symposium 2a	Break symposium 2b	Break symposium 2c	Break symposium 2d
15:30	GI Vessel Hemorrhage	Non-HCC Tumor	Vascular Intervention Aorta	APSCVIR meet KSIR
15:30
15:45
16:00
16:30
16:45
17:00
17:00-18:00	Interactive quiz session

8:30	SIR Leadership Update Michael D. Dake/USA
8:45	SIR Strategic Plan Keith M. Hume/USA
9:00	SIR International Outreach- Year in Review Brian F. Stainken/USA
9:05	SIR International Outreach- A Look Ahead JConstantinos T. Sofocleous/USA
9:15	SIR Foundation Leadership Update Katharine L. Krol/USA
9:30	SIR 2021- Annual Scientific Meeting Constantino S. Tino Pena /USA
9:45	Q & A

10:30	Mesenteric Ischaemia treatment (acute or chronic) Stephen Merrilees/NZ
10:43	SMA occlusion: Treatment with a thrombectomy catheter Lawrence Quek/Singapore
10:56	Treatment of portal vein thrombosi Edward Wolfgang Lee/USA
11:09	Trans-Splenic Portal Vein Reconstruction Matthew S. Johnson/USA
11:22	TIPS for the treatment of cavernous trans formation of portal vein with symptomatic portal hypertension Fei Gao/China.
11:35	Mesenteric Re-vascularization: When and how? Brian F. Stainken/USA
11:48	Primary catheter-directed thrombolysis for porto-mesenteric venous thrombosis (PMVT) in non-cirrhotic patients Huei-Lung Liang/Taiwan

10:30	Imaging approach for improving the therapeutic effect of TACE Shingo Kakeda/Japan
10:42	Update on combination treatment for HCC Ivan Huang/Singapore
10:54	Combination therapy for liver tumours Apoorva Gogna/Singapore
11:06	Y-90 Radioembolization Combined with a PD-1 Inhibitor for Advanced Hepatocellular Carcinoma Su Pin Choo/Singapore
11:18	TACE for HCC: Indian perspective Arun Gupta/India.
11:30	Hepatic artery embolization and immune modulation Haruyuki Takaki/Japan.
11:42	Various embolization techniques using novel calibrated gelatin microparticles Chang-Won Kim/Korea.
11:54	How I treat HCC using de-TACE? Dong IL Gwon/Korea
12:06	Development of radiopaque drug-eluting beads based on lipiodol/biodegradable-polymer for transarterial chemoembolization Terumitsu Hasebe/Japan

10:30	IR in Children - not a mini-adult Joao Amaral/Canada
10:40	Vascular hepatic interventions (including transplant) Manish Patel/USA
10:55	Non-vascular hepatic interventions (including transplant) Shunsuke Nosaka/Japan
11:10	Vascular Gastrointestinal interventions Dennis C. Villanueva/Philippines
11:25	Non-vascular Gastrointestinal interventions Dimitri A. Parra/Canada
11:40	Case discussion Chia-Ling Chiang/Taiwan
11:50	SPIR: resources for supporting your PIR practice Luke Toh Han Wei

13:30	Role of interventional radiologist in living donor liver transplant Hsin-You Ou/Taiwan
13:50	Interventional radiology for pediatric patients after liver transplantation Shunsuke Nosaka/Japan
14:10	Intervention management of biliary complications in right liver graft Ungbae Jeon/Korea
14:30	Downstaging of hepatocellular carcinoma in living donor liver transplant Chun-Yen Yu/Taiwan
14:50	Q & A

10:30	Radioembolization as part of the algorithm for the treatment of HCC Constantinos T. Sofocleous /USA
10:45	The mapping angiogram: hepatic anatomy & extrahepatic arteries Nadine Abi-Jaoudeh/U
10:55	Hepatocellular carcinoma (HCC) with glass: How I do it Matthew S. Johnson/USA
11:05	Hepatocellular carcinoma (HCC) with resin: How I do it Brian F. Stainken/USA
11:15	M&M - our complications and how we manage them

11:30	Segmental radioembolization of HCC Chien-An Liu/Tw
11:45	CT-guided RFA for HCC after Y-90 SIRT down-staging Po-Chin Liang/Tw
12:00	RESIN registry in Taiwan Rheun Chuan Lee /Tw

13:30	Alex Tang: Kuala Lumpur, Malaysia：
13:45	Xiaodong Wang
14:00	Koichiro Yamakado
14:15	Zhi-ping Yan:
14:30	New Zeland
14:45	Q & A

13:30	Endovascular management of type II endoleak of EVAR/ TEVAR and timing- Japan Experience Norio Hongo/Japan
13:45	Endovascular management of type II endoleak of EVAR/ TEVAR and timing -Singapore Experience Kiang-Hiong Tay/Singapore
14:00	Endovascular management of type II endoleak of EVAR/ TEVAR and timing -Taiwan Experience Sung-Yu Chu/Taiwan
14:15	The road to preventing type Ⅱ endoleak prior to EVAR. Masato Yamaguchi/Japan
14:30	Safety and efficacy Of Covered Endovascular Reconstruction Of The Aortic Bifurcation (CERAB) Technique For Complex Aortoiliac Occlusive Disease: A Single Center Experience Maria Antonella Ruffino/ Italy
14:45	Endovascular Reconstruction of Complex Aorto-iliac Occlusive Disease with Covered Balloon Expandable Endoprostheses – An Update. Andrew Holden/NZ

15:30	Step by step angiography of upper and lower GI bleedings: expert experience Romaric Loffroy/France.
15:43	Pitfalls of GI Bleeding Management Dennis C. Villanueva/Philippines
15:56	Current updates in management of upper GI bleeding Kristen Alexa Lee/Singapore
16:09	Is there a role for empirical embolization of upper GI ble Lik-Fai Cheng/Hongkong
16:22	Embolisation for acute lower GI haemorrhage Robert A. Morgan/UK.
16:35	Safety & Efficacy of TAE for low GI bleeding Jin-Wook Chung/Korea.
16:48	Empiric embolizatiion for LGI bleeding Huei-Lung Liang/Taiwan

15:30	New Techniques of Intraarterial therapy for colorectal liver metastasis Hideyuki Nishiofuku/Japan
15:42	Drug-eluting bead TACE for mCRC Toshihiro Tanaka/Japan
15:54	Optimising Patient outcomes with Selective Internal Radiation Therapy. Lourens Bester/Australia
16:06	RFA for liver metastasis Koichiro Yamakado/Japan
16:18	CT-guided percutaneous microwave ablation for liver tumors Gordon Bin Liu/China
16:30	Irreversible electroporation for pancreas cancer Man-Deuk Kim/Korea
16:42	Expanding areas of cryoablation Afshin Gangi/France
16:54	cryoablation, Endocare TBA
17:06	Ablation of the thyroid nodules Wei-Che Lin/Taiwan

15:30	In-situ Fenestration and Scallops in the Treatment of Disease of the Aortic Arch Van Den Berg Josua/Switzerland
15:45	Tips and tricks : how to cannulate the contra-lateral limb during EVAR in difficult vascular anatomy. Jae-Kyu Kim/Korea
16:00	IR management of malperfusion syndrome in aortic dissection Kiang-Hiong Tay/Singapore.
16:15	Experience of the anaconda fenestrated device for the treatment of abdominal aortic aneurysm. Raghuram Lakshminarayan/UK
16:30	Fenestrated TVAR. Rochan Pant/India.

15:30	Endovascular treatment in acute TBAD Kwang-Hun Lee/Korea
15:40	Alternative techniques for complex BTK lesions Je Hwan Won/Korea
15:50	Boosted radioembolization for HCC: when, why, and how? Hyo-Cheol Kim/Korea
16:00	Preoperative embolization plus surgical excision of AVM Sang Yub Lee/Korea
16:10	Percutaneous treatment of endometriomas Man-Deuk Kim/Korea
16:20	Irreversible electroporation for pancreas cancer Man-Deuk Kim/Korea
16:30	Embolization for postpartum hemorrhage: recent update Ji Hoon Shin/Korea
16:40	Embolotherapy for chylothorax Dongho Hyun/Korea
16:50	Embolotherapy for lymphatic ascites Jinoo Kim/Korea
17:00	Q & A

13:30-13:38	ZhichengJin	China	Machine-learning analysis of contrast-enhanced CT radiomics predicts hepatocellular carcinoma patients unsuitable for initial transarterial chemoembolization monotherapy: A multicentre study
13:38-13:46	ZhichengJin	China	Radiomic analysis of contrast-enhanced CT predicts refractoriness to first TACE in HCC
13:46-13:54	Sheng Xu	China	The survival prediction for hepatocellular carcinoma patients treated with microwave ablation and transcatheter arterial chemoembolization.
13:54-14:02	Peng Zeng	China	125I Combined with DCs Loaded with Tumor Antigen Converts Irradiated Tumors into Effective In Situ Vaccines
14:02-14:10	Ibrahim Alrashidi	Saudi Arabia	Best response during repeated chemoembolization is the most significant predictor of survival in hepatocellular carcinoma
14:10-15:00	Q&A